Quantifying Inflammation Using Interleukin-6 for Improved Phenotyping and Risk Stratification in Acute Heart Failure
Authors:
- 16 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 25 (2) , 174-184
Abstract
Aims: Systemic inflammation may be central in the pathophysiology of acute heart failure (AHF). We aimed to assess the possible role of systemic inflammation in the pathophysiology, phenotyping, and risk stratification of patients with AHF. Methods and results: Using a novel Interleukin-6 immunoassay with unprecedented sensitivity (limit of detection 0.01 ng/L), we quantified systemic inflammation in unselected patients presenting with acute dyspnoea to the emergency department in a multicentre study. One-year mortality was the primary prognostic endpoint. Among 2042 patients, 1026 (50.2%) had an adjudicated diagnosis of AHF, 83.7% of whom had elevated interleukin-6 concentrations (>4.45 ng/L). Interleukin-6 was significantly higher in AHF patients compared to patients with other causes of dyspnoea (11.2 [6.1–26.5] ng/L vs. 9.0 [3.2–32.3] ng/L, p < 0.0005). Elevated interleukin-6 concentrations were independently predicted by increasing N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T, as well as the clinical diagnosis of infection. Among the different AHF phenotypes, interleukin-6 concentrations were highest in patients with cardiogenic shock (25.7 [14.0–164.2] ng/L) and lowest in patients with hypertensive AHF (9.3 [4.8–21.6] ng/L, p = 0.001). Inflammation as quantified by interleukin-6 was a strong and independent predictor of 1-year mortality both in all AHF patients, as well as those without clinically overt infection at presentation (adjusted hazard ratio [95% confidence interval] 1.45 [1.15–1.83] vs. 1.48 [1.09–2.00]). The addition of interleukin-6 significantly improved the discrimination of the BIOSTAT-CHF risk score. Conclusion: An unexpectedly high percentage of patients with AHF have subclinical systemic inflammation as quantified by interleukin-6, which seems to contribute to AHF phenotype and to the risk of death.Keywords
Funding Information
- Brahms
- Cardiovascular Research Foundation Basel
- Research Grants from the European Union
- Roche
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Singulex
- Swiss Heart Foundation
- Swiss National Science Foundation
- Universitätsspital Basel
- University of Basel
- Roche
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Singulex
- Schweizerische Herzstiftung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Universitätsspital Basel
- Universität Basel
This publication has 36 references indexed in Scilit:
- Reference range and short- and long-term biological variation of interleukin (IL)-6, IL-17A and tissue necrosis factor-alpha using high sensitivity assaysCytokine, 2013
- Implications of Adjustment of High-Sensitivity Cardiac Troponin T AssayClinical Chemistry, 2013
- Neurohormonal Activation in Acute Heart Failure: Results from VERITASCardiology, 2011
- Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in RatsHypertension, 2010
- Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of AtherosclerosisEuropean Heart Journal, 2010
- Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic CellsJournal of Virology, 2009
- Ultrasensitive Flow-based Immunoassays Using Single-Molecule CountingClinical Chemistry, 2007
- Time-course of changes in levels of interleukin 6 in acutely decompensated heart failureInternational Journal of Cardiology, 2006
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric OxideScience, 1992